Lead elimination of ICRF 158 in rats after chronic lead exposure.
Lead elimination by ICRF 158, a lipophilic derivative of ethylene-diaminetetra-acetate (EDTA), was investigated in rats after chronic lead exposure. The animals had received a lead concentration of 550 ppm in their drinking water for 140 days. Subsequent treatment with ICRF 158 for 30 days led to increased mobilization and elimination of incorporated lead, and the lead-induced inhibition of hemosynthesis was removed. ICR 158 produced no renal damage in excess of lead-induced tubular nephrosis. Separate toxicity tests in mice demonstrated that it is less toxic than CaNa2EDTA. ICRF 158 does not form stable complexes with lead ions in vitro. The mechanism of action of this lipophilic EDTA derivative is compared to that of its hydrophilic correspondent, the chelating agent CaNa2EDTA.
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use*; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D007668:Kidney / Q000378:metabolism; D007854:Lead / Q000378:metabolism*; D007855:Lead Poisoning / Q000188:drug therapy*; D008099:Liver / Q000378:metabolism; D008297:Male; D051381:Rats
D002614:Chelating Agents; D007854:Lead; C029282:4,4'-ethylenebis(1-methyl-2,6-piperazinedione); D004492:Edetic Acid